Oncogenes | Jotup

Affimed Reports Progress on Key Clinical Development Programs

Retrieved on:

Tuesday, October 15, 2019

Medicine, Clinical medicine, Cancer, Epidermal growth factor receptor, Oncogenes, Targeted therapy, Oncology, Cancer immunotherapy

The IND filing is an important step toward the development of AFM24, our innate cell engager designed to target EGFR-expressing cancers, including those with resistance to existing EGFR-targeted therapies.

Key Points:

The IND filing is an important step toward the development of AFM24, our innate cell engager designed to target EGFR-expressing cancers, including those with resistance to existing EGFR-targeted therapies.
According to internal market research, leading clinical experts across multiple cancer indications see a tremendous need for novel immuno-oncology approaches for the treatment of solid tumors.
The clearance of the IND for AFM13 pre-mixed with cord blood-derived NK cells is a significant milestone in our overall clinical development plan.
Affimed (Nasdaq: AFMD) is a clinical stage biopharmaceutical company committed to giving patients back their innate ability to fight cancer.

Ryan Schonfeld of RAS Security Group to Launch One of a Kind Global Managed Service Operations and Risk Mitigation Center

Retrieved on:

Monday, October 14, 2019

Security engineering, Cyberwarfare, National security, Oncogenes, Ras GTPase, Computer security, Security, Prevention

LOS ANGELES, Oct. 14, 2019 (GLOBE NEWSWIRE) -- Ryan Schonfeld, founder & CEO of RAS Security Group , a leader in state-of-the-art risk management services and operations, today announced the launch of RAS Watch (Watch), the first of its kind managed service operations and risk mitigation center in the security space.

Key Points:

LOS ANGELES, Oct. 14, 2019 (GLOBE NEWSWIRE) -- Ryan Schonfeld, founder & CEO of RAS Security Group , a leader in state-of-the-art risk management services and operations, today announced the launch of RAS Watch (Watch), the first of its kind managed service operations and risk mitigation center in the security space.
RAS Security Group CEO Schonfeld states, RAS Watch intends to shift companies from a historically, reactive security posture to a fully-alert and proactive one.
Innovative in its approach as a subscription service, Watch is the first of its kind in the security industry.
Providing business leadership with actionable intelligence, RAS Watch is a member of the RAS Security Group family.

Forbius: Phase 2 Clinical Data with Tumor-Selective Anti-EGFR ADC AVID100 Featured at AACR-NCI-EORTC and World ADC San Diego

Retrieved on:

Thursday, October 10, 2019

We are focused on the transforming growth factor-beta (TGF-beta) and epidermal growth factor receptor (EGFR) pathways.

Key Points:

We are focused on the transforming growth factor-beta (TGF-beta) and epidermal growth factor receptor (EGFR) pathways.
Forbius team of TGF-beta biology experts designed a proprietary platform of TGF-beta inhibitors with best-in-class potency and selectivity against the principal disease-driving isoforms 1 & 3.
Forbius lead TGF-beta 1 & 3 inhibitor, AVID200, is undergoing Phase 1 clinical trials in two fibrotic indications as well as in solid tumors.
AVID100 is an anti-EGFR antibody-drug conjugate (ADC) with a novel tumor-selective mode of action.

New Data Presented on ASLAN’s varlitinib at ESMO 2019

Retrieved on:

Wednesday, October 2, 2019

Tyrosine kinase receptors, Branches of biology, Medicine, Oncogenes, Clinical medicine, Epidermal growth factor receptor, HER2/neu, Immune checkpoint, Trastuzumab, Gefitinib

Varlitinib (ASLAN001) is a highly potent, oral, reversible, small molecule pan-HER inhibitor that targets the human epidermal growth factor receptors HER1, HER2 and HER4.

Key Points:

Varlitinib (ASLAN001) is a highly potent, oral, reversible, small molecule pan-HER inhibitor that targets the human epidermal growth factor receptors HER1, HER2 and HER4.
These receptors can be mutated or overexpressed in many tumours, which can cause excessive proliferative activity and uncontrolled growth.
Therefore, by inhibiting the activation of the HER receptors, varlitinib could inhibit proliferation and control tumour growth.
ASLANs clinical portfolio is comprised of three product candidates which target validated growth pathways applied to new patient segments, novel immune checkpoints and novel cancer metabolic pathways.

Cellectar Presents Data from DLBCL Cohort of its Phase 2 CLOVER-1 Study at the European Society for Medical Oncology (ESMO) Congress

Retrieved on:

Monday, September 30, 2019

Branches of biology, Oncogenes, Oncology, Bcl-2, Programmed cell death, Myc, Response rate

Data showed durable responses, including a 33% overall response rate (ORR), a 16.6% complete response rate (CR) and a 50% clinical benefit rate (CBR).

Key Points:

Data showed durable responses, including a 33% overall response rate (ORR), a 16.6% complete response rate (CR) and a 50% clinical benefit rate (CBR).
In a patient for whom cytogenetics was available, CLR 131 showed activity against c-Myc and BCL-2 mutation (single & dual-hit) positive patients.
Cellectar was awarded approximately $2 million in non-dilutive grant funding from the National Cancer Institute to help fund the trial.
The companys lead PDC therapeutic, CLR 131, is currently in three clinical studies a Phase 2 study, and two Phase 1 studies.

Data Presented at ESMO Show Metastatic CRC Patients with HER2 Amplification Detected by Guardant360 Experience Clinical Benefit After Targeted Therapy

Retrieved on:

Saturday, September 28, 2019

Tyrosine kinase receptors, Cancer, Oncogenes, Branches of biology, Clinical medicine, Cancer treatments, HER2/neu, Epidermal growth factor receptor, ErbB, Trastuzumab, Pertuzumab

Study showed that patients with metastatic colorectal cancer (mCRC) with a HER2 (ERBB2) amplification detected by the Guardant360 assay experienced clinical benefit from National Comprehensive Cancer Network (NCCN) guideline-recommended HER2-directed combination therapy.

Key Points:

Study showed that patients with metastatic colorectal cancer (mCRC) with a HER2 (ERBB2) amplification detected by the Guardant360 assay experienced clinical benefit from National Comprehensive Cancer Network (NCCN) guideline-recommended HER2-directed combination therapy.
The study, to be presented at a poster discussion session on September 29, included patients with RAS-wild-type mCRC refractory to standard EGFR-directed therapies, and HER2 amplification detected using standard tissue-based testing or Guardant360.
Excluding patients with known markers of resistance detected by Guardant360, the ORR was 45.5% (95% CI, 16.7-76.6%).
Virtually no patients tumors with advanced CRC are tested for HER2 amplification unless they are getting next-generation sequencing.

Aileron Presents Positive Interim Phase 2a Data for ALRN-6924 in Combination with Pfizer’s Palbociclib at the 2019 Congress of the European Society for Medical Oncology

Retrieved on:

Saturday, September 28, 2019

Branches of biology, Proteins, Mdm2, Oncogenes, Liposarcoma, Biology

As of the data cutoff date of September 2, 2019, the trial had enrolled 26 patients.

Key Points:

As of the data cutoff date of September 2, 2019, the trial had enrolled 26 patients.
The vast majority of patients enrolled thus far are sarcoma patients, including 20 with liposarcoma, as MDM2 amplification or MDM2/CDK4 co-amplification is very often found in this tumor type.
The reported safety results show that the combination has been very well-tolerated in the trial, with the most common non-hematological related adverse events grade 2 being nausea (46%) and fatigue (23%).
Aileron expects to announce a final data readout in the second quarter of 2020.

Onconova Therapeutics Announces Presentation on Rigosertib at the RAS-Targeted Drug Discovery Summit

Retrieved on:

Monday, September 16, 2019

RTT, Oncogenes, KRAS, Ras GTPase, Cancer, Colorectal cancer, Causes of death, Branches of biology, Clinical medicine

The RAS-Targeted Drug Discovery Summit provides an opportunity to showcase the potential for rigosertib in MDS and in other RAS-driven cancers, such as KRAS-mutated lung cancer and colorectal cancer, and Ras- driven pediatric cancers as well.

Key Points:

The RAS-Targeted Drug Discovery Summit provides an opportunity to showcase the potential for rigosertib in MDS and in other RAS-driven cancers, such as KRAS-mutated lung cancer and colorectal cancer, and Ras- driven pediatric cancers as well.
Onconovas representatives look forward to joining colleagues at the Summit to discuss advancements in rigosertibs development and the progress the Company and others have made in targeting RAS.
Onconova Therapeutics, Inc. is a Phase 3-stage biopharmaceutical company discovering and developing novel small molecule drug candidates to treat cancer, with a focus on Myelodysplastic Syndromes (MDS).
Advanced clinical trials with the Companys lead compound, rigosertib, are aimed at what the Company believes are unmet medical needs of patients with MDS.

Spectrum Announces Poziotinib Data Being Presented at the IASLC 2019 World Conference on Lung Cancer

Retrieved on:

Friday, September 6, 2019

New clinical data from the poziotinib Phase 2 investigator-initiated trial in NSCLC EGFR exon 20 mutations, conducted by the University of Texas MD Anderson Cancer Center will be presented during the IASLC 2019 World Conference on Lung Cancer hosted by the International Association for the Study of Lung Cancer taking place in Barcelona, Spain from September 7-10, 2019.

Key Points:

New clinical data from the poziotinib Phase 2 investigator-initiated trial in NSCLC EGFR exon 20 mutations, conducted by the University of Texas MD Anderson Cancer Center will be presented during the IASLC 2019 World Conference on Lung Cancer hosted by the International Association for the Study of Lung Cancer taking place in Barcelona, Spain from September 7-10, 2019.
The data presented at this conference by our scientific collaborators at MD Anderson further expands the body of evidence supporting poziotinibs role in lung cancer and helps us gain new insights into its full potential.
Mutations or overexpression/amplification of EGFR family receptors have been associated with a number of different cancers, including non-small cell lung cancer (NSCLC), breast cancer, and gastric cancer.
REDEFINING CANCER CARE and the Spectrum Pharmaceuticals logos are trademarks owned by Spectrum Pharmaceuticals, Inc. Any other trademarks are the property of their respective owners.

Aileron Therapeutics to Present at the H.C. Wainwright 21st Annual Global Investment Conference in New York

Retrieved on:

Tuesday, September 3, 2019

Proteins, Mdm2, Oncogenes, ATM serine/threonine kinase

ALRN-6924 is currently being evaluated in multiple clinical trials for the treatment of a variety of cancers, including cancers with MDM2-amplified tumors.

Key Points:

ALRN-6924 is currently being evaluated in multiple clinical trials for the treatment of a variety of cancers, including cancers with MDM2-amplified tumors.
For information about Ailerons clinical trials, please visit www.clinicaltrials.gov .
Aileron is a clinical-stage biopharmaceutical company advancing a proprietary platform of cell-permeating alpha-helical peptides that address the most important intracellular targets in oncology and other therapeutic areas.
The stabilized helical structure of our peptides allows the design of cell-permeating therapeutic agents with large molecular surfaces for optimal target binding properties, resulting in unique drugs like ALRN-6924.